Results 101 to 110 of about 217,476 (395)

Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study. [PDF]

, 2017
Background: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive.Methods: We identified a large ...
Demissie, Kitaw, E, Jian-Yu, Graber, Judith M., Lin, Yong, Lu, Shou-En, Lu-Yao, Grace, Petersen, Gloria M., Rotter, David, Tan, Xiang-Lin, Zhang, Lanjing   +9 more
core   +2 more sources

Surgical Treatment of Pancreatic Ductal Adenocarcinoma

Cancers, 2021
Simple Summary Surgery is the only potential cure for pancreatic ductal adenocarcinoma and should always be combined with adjuvant chemotherapy or other multimodal treatment.
Kongyuan Wei, T. Hackert
semanticscholar   +1 more source

Bioprinting Organs—Science or Fiction?—A Review From Students to Students

Advanced Healthcare Materials, EarlyView.
Bioprinting artificial organs has the potential to revolutionize the medical field. This is a comprehensive review of the bioprinting workflow delving into the latest advancements in bioinks, materials and bioprinting techniques, exploring the critical stages of tissue maturation and functionality.
Nicoletta Murenu, Camilla Mussoni, Mateo S. Andrade Mier, Paula Buettner, Nathaly Chicaiza‐Cabezas, Yi‐Yu Robin Dai, Jessica Faber, Maren Fiedler, Zan Lamberger, Xuen Jen Ng, Vanessa Moessler, Anna Rederer, Jonas Roeder, Sabrina Stecher, Katinka Theis, Jeanette Weigelt, Silvia Budday, Gregor Lang, Natascha Schaefer   +18 more
wiley   +1 more source

Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models

Surgery Open Science, 2019
Background: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer.
Mayrim V. Rios Perez, David Roife, Bingbing Dai, Michael Pratt, Ryszard Dobrowolski, Ya'an Kang, Xinqun Li, Jithesh J. Augustine, Rafal Zielinski, Waldemar Priebe, Jason B. Fleming   +10 more
doaj   +1 more source

The dark side of ferroptosis in pancreatic cancer

OncoImmunology, 2021
Drug-induced ferroptosis, an iron-dependent regulatory necrosis, has been proposed for the therapy of pancreatic ductal adenocarcinoma. However, genetically engineered mouse models have revealed that high-iron diets or deletion of pancreatic GPX4 (a key ...
Jiao Liu, Enyong Dai, Rui Kang, Guido Kroemer, Daolin Tang   +4 more
doaj   +1 more source

Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment

Current Problems in Cancer: Case Reports, 2022
Background: Acinar cell carcinoma of the pancreas (ACC) is a rare malignancy, accounting for approximately 1-2% of all pancreatic cancers. Up to a quarter of ACCs are estimated to contain a significant component of another histology such as ...
Abdullah Nasser, Catherine L. Forse, Cynthia Walsh, Terence Moyana, Rakesh Goel   +4 more
doaj   +1 more source

RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis [PDF]

, 2016
Tumor suppression that is mediated by oncogene-induced senescence (OIS) is considered to function as a safeguard during development of pancreatic ductal adenocarcinoma (PDAC). However, the mechanisms that regulate OIS in PDAC are poorly understood. Here,
Algül, Hana, Demir, Ihsan Ekin, Diakopoulos, Kalliope Nina, Einwächter, Henrik, Heikenwälder, Mathias, Kehl, Timo, Korneeva, Olga, Lesina, Marina, Morton, Jennifer, Sansom, Owen J., Saur, Dieter, Schmid, Roland Michael, Sipos, Bence, Sperveslage, Jan, Steiner, Jörg Manfred, Wang, Timothy Cragin, Wimmer, Margit, Wörmann, Sonja Maria   +17 more
core   +1 more source

Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies

Advanced Healthcare Materials, EarlyView.
Bioengineering tumor‐stroma pancreatic cancer models with potential to emulate the native immunosuppressive tumor microenvironment. Cancer‐on‐a‐bead models exhibited higher relevance for screening immunotherapies and modulating the protumoral PDAC microenvironment. ABSTRACT Pancreatic cancer is notably resistant to treatment, primarily due to its dense
Maria V. Monteiro, Margarida Henriques‐Pereira, Bruno M. Neves, Vítor M. Gaspar, João F. Mano   +4 more
wiley   +1 more source

Current and Future Therapies for Pancreatic Ductal Adenocarcinoma [PDF]

, 2022
Áine Sally, Ryan McGowan, Karen Finn, Brian M. Moran   +3 more
openalex   +1 more source

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches

Radiation Oncology, 2019
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor prognosis and rising incidence. Late detection and a particularly aggressive biology are the major challenges which determine therapeutic failure.
M. Orth, P. Metzger, S. Gerum, J. Mayerle, G. Schneider, C. Belka, M. Schnurr, K. Lauber   +7 more
semanticscholar   +1 more source